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ABSTRACT 
 
Glycated albumin as an indicator of glycemic control in pre-dialysis 
diabetic chronic kidney disease patients 
 
Sung Chang Bae 
 
Department of Medicine 
The Graduate School, Yonsei University  
 
(Directed by Professor Hyeong Cheon Park) 
 
Background Good glycemic control in diabetic patients is important to 
prevent progression of diabetic nephropathy and reduce cardiovascular events. 
Recently, several studies suggested that hemoglobin A1c (HbA1c), a widely 
used glycemic control marker, has serious limitations by falsely 
underestimating glycemic state in diabetic patients on hemodialysis. In contrast, 
glycated albumin (GA), which is not influenced by diseases of shortened RBC 
life span, and use of iron supplements and erythropoietin (EPO) therapy, is 
thought to more accurately reflect glycemic state in ESRD patients. Study aim 
was to validate this finding in pre-dialysis diabetic chronic kidney disease 
(CKD) patients. 
 
Methods Clinically stable pre-dialysis type 2 diabetic patients were enrolled 
between March 2009 and August 2012. A total of 497 patients were enrolled 
and stratified into 5 groups according to 2012 KDIGO CKD guideline that 
subdivided stage 3 into 3a and 3b stages. Parameters of glycemic control were 
investigated along with other biochemical and clinical informations. 
 
Results The numbers of patients according to CKD stages 1 to 4-5 were 
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consisted of 168, 151, 76, 47, and 55 subjects, respectively. The mean serum 
glucose concentrations did not differ significantly among 5 groups. The HbA1c 
and GA showed positive correlations at all CKD stages, however, increased 
steepness in slope of regression line between HbA1c and GA with decline in 
renal function was shown (control group vs. other CKD stages: p < 0.05). The 
GA/HbA1c and serum glucose/HbA1c in CKD stage 3b and 4-5 were 
significantly higher than in controls, and the GA/HbA1c increased (r = 0.22, p < 
0.001) with progression of renal failure. In contrast, the GA and glucose/GA 
remained constant throughout the all CKD stages. In multivariate analysis, 
weekly erythropoietin dose (p = 0.02) was associated with HbA1c and, the cut 
off value in ROC curve of weekly EPO dose altered HbA1c level was 6000 
U/week (AUC = 0.91, 95% CI 0.78 - 1.00). 
 
Conclusion Our results indicate that the HbA1c may underestimate glycemic 
control state even in pre-dialysis diabetic CKD patients, especially those who 
are on EPO treatment and the GA might be an useful indicator of glycemic 
control in pre-dialysis diabetic CKD patients. 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------- 
Key words : diabetic nephropathy, glycated hemoglobin, glycated albumin 
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I. INTRODUCTION 
Diabetes mellitus (DM) is the leading cause of end-stage renal disease (ESRD) 
in Korea.1 The proportion of incident ESRD patients with DM has increased from 
less than 30 % in early 1990s to almost 50 % in 2011. Good glycemic control in 
diabetic patients is important to prevent progression of diabetic nephropathy and 
reduce cardiovascular events. Strict glycemic control has been associated with 
improved quality of life and survival.2, 3 The 2012 updated Kidney Disease 
Outcomes Quality Initiative (KDOQI) clinical practice guideline for diabetes and 
chronic kidney disease (CKD) recommend a target hemoglobin A1c (HbA1c) 
level of 7.0 % in diabetic CKD patients to prevent or delay progression of the 
microvascular complications.4 The HbA1c is currently the most widely used 
glycemic control marker. It is formed by combination of hemoglobin with the 
circulating serum glucose via irreversible non-enzymatic reaction,5 and reflects 
glycemic state over the prior 120 days.6, 7 However, the HbA1c measurement is 
influenced by diseases of shortened RBC life span,8 and use of iron supplements 
and EPO therapy. Patients with these risk factors frequently show reduced HbA1c 
levels and clinicians may falsely underestimate their glycemic state.9 Glycated 
albumin (GA), the product of condensation of albumin and glucose, reflects 
glycemic state over a short period of preceding 2–3 weeks and is not influenced 
4 
 
by RBC survival time.10 Recently, several clinical trials provided evidence that 
GA provides more accurate index of the glycemic control in advanced CKD 
patients. Furthermore, the GA predicted the risk of death and hospitalization in 
hemodialysis patients.11 However, the significance of GA as a marker of 
glycemic control in pre-dialysis diabetic CKD patients has not been thoroughly 
investigated yet.12, 13 
Our study attempts to validate whether the GA is more suitable than the HbA1c 
as an indicator of glycemic control in pre-dialysis diabetic CKD patients. 
 
II. MATERIALS AND METHODS 
1. Patients 
Clinically stable pre-dialysis type 2 diabetic patients treated at Gangnam 
Severance Hospital, South Korea were enrolled between March 2009 and August 
2012. This study was composed of 329 pre-dialysis CKD patients with type 2 
diabetes, and 168 patients with type 2 diabetes and normal renal function. The 
diagnosis of diabetes was based on medical records or criteria in the Report of the 
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.14 All 
medications, including oral hypoglycemic agents, insulin or erythropoietin (EPO), 
had not been altered within 3 months prior to measurement of the HbA1c and GA. 
Patients were stratified into 5 groups according to 2012 Kidney Disease Improving 
Global Outcome (KDIGO) CKD guideline. Estimated GFR (eGFR, ml/min per 
1.73 m2) was calculated using the 4-variable Modification of Diet and Renal 
Disease (MDRD) study equation.15 CKD stage 3 was further subdivided into 3a 
and 3b as recent data demonstrated substantial differences in those who have 
eGFR values between 45 and 60 versus 30 and 45 ml/min per 1.73 m2.16 
Demographic and medical information including age, gender, height, weight, body 
mass index (BMI), weekly EPO dose and other medications were collected at 
baseline from electronic medical records. Parameters of glycemic control, HbA1c 
and GA, as well as fasting serum glucose, hemoglobin, blood urea nitrogen, 
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creatinine, total protein, albumin and urine protein were assessed. The mean value 
of the 3 monthly measurements of fasting serum glucose prior to determination of 
HbA1c and GA were used in this study.17 Exclusion criteria were age under 18 or 
older than 90 years old, hemoglobinopathy, anemia not associated with CKD, 
chronic liver disease, endocrinopathy including thyroid disease, adrenal disease, 
pregnancy, recent infection, pre-existing malignancy and kidney transplantation.13 
The patients who have taken medications that could influence serum glucose 
concentration within three months prior to the study were also excluded. This 
study was approved by Institutional Review Board for Human Research at Yonsei 
University College of Medicine (#IRB 3-2014-0150). 
 
2. Assay of HbA1c and GA 
Parameters of glycemic control, HbA1c and GA, were measured along with other 
biochemical and clinical parameters. The HbA1c level was analyzed using the 
Automated Glyco-hemoglobin Analyzer, HLC-723G8 (Tosoh corp., Tokyo, 
Japan), a high performance liquid chromatography system designed to measure 
HbA1c. The GA level was measured by an enzymatic method that converts GA to 
glycated amino acids using the Lucica GA-L kit (Asahi Kasei Pharma Corp., 
Tokyo, Japan). The GA was calculated as the percentage of GA relative to total 
albumin. 
 
3. Statistical Analyses 
All values are expressed as means ± standard deviations (SD) or number and 
percentages. Statistical analysis was performed using SPSS for Windows Ver. 
17.0 (SPSS, Inc., Chicago, IL, USA). The comparisons of HbA1c, GA and other 
continuous variables between the patients at different CKD stages and controls 
were analyzed by independent t-test. Pearson’s correlation coefficients were 
calculated for evaluation of correlation between glycemic parameters by simple 
regression analysis. In addition, independent factors associated with the HbA1c 
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and GA were determined by multiple linear regression analysis. Furthermore, the 
cut-off values of weekly EPO dose were evaluated by constructing receiver 
operating characteristic (ROC) curve. The p-values less than 0.05 were 
considered to be statistically significant. 
 
III. RESULTS 
Blood samples were collected from 497 diabetic patients, 329 were pre-dialysis 
diabetic CKD patients and 168 were diabetic patients without nephropathy. 
 
 
 
Demographic and laboratory characteristics of study population are summarized 
in Table 1. All patients were stratified into 5 groups,16 and the continuous 
variables in CKD groups including stage 2, 3a, 3b and 4-5 were compared with the 
results in diabetic controls without nephropathy. The number of patients in 
controls and CKD stage 2, 3a, 3b and 4-5 were consisted of 168, 151, 76, 47 and 
55 subjects, respectively. Diabetic controls had an eGFR of 99.3 ± 11.0 ml/min 
per 1.73 m2 and the eGFR in CKD stage 2, 3a, 3b and 4-5 were 77.3 ± 7.7, 53.5 ± 
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4.4, 37.8 ± 4.7 and 22.9 ± 6.3 ml/min per 1.73 m2, respectively. Worsening of 
anemia was observed in advanced CKD stages, the hemoglobin level in CKD 
stage 3a (12.9 ± 2.3 g/dL), 3b (12.0 ± 1.7 g/dL) and 4-5 (10.9 ± 1.3 g/dL) was 
significantly lower than the controls (13.8 ± 2.6 g/dL). The number of patients 
receiving EPO supplementation increased as their renal function worsened. Less 
than 3 % of patients in stage 3a were receiving EPO. In contrast, up to 40 % of 
patients in stage 4-5 were receiving EPO supplementation and mean weakly dose 
of EPO in stage 3a, 3b, and 4-5 were 72.37 ± 445.0, 579.8 ± 1474.5 and 1259.1 ± 
1976.1 U/week, respectively. A similar results were observed for the serum 
albumin with significantly lower levels in CKD stage 3b (4.3 ± 0.3 g/dL) and 4-5 
(4.0 ± 0.5 g/dL) than the controls (4.4 ± 0.4 g/dL). In addition, urine protein in 
CKD stage 3a (482.4 ± 940.7 mg/day), 3b (1020.4 ± 2070.6 mg/day) and 4-5 
(2128.7 ± 3026.1 mg/day) was significantly higher than the controls (70.3 ± 499.4 
mg/day). Interestingly, 15 patients (3%) showed nephrotic range proteinuria and 
they were found in CKD stage 1 (n = 1), 2 (n = 1), 3a (n = 1), 3b (n = 3) and 4-5 (n 
= 9), respectively. 
 
 
 
Table 2 summarizes the parameters of glycemic control in study patients. The 
last three monthly fasting serum glucose concentrations did not differ significantly 
among 5 groups. Also, the GA and serum glucose/GA ratio were constant 
throughout all of 5 groups. In contrast, the HbA1c level in CKD stage 4-5 (6.9 ± 
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1.1 %) was significantly lower than the controls (7.4 ± 1.6 %), and the GA/HbA1c 
and serum glucose/HbA1c ratio in CKD stage 4-5 were 3.0 ± 0.6 and 20.8 ± 4.9, 
respectively, all of which were significantly higher than the corresponding results 
of 2.5 ± 0.4 and 18.2 ± 2.8 in diabetic controls. 
 
 
 
Figure 1 shows the correlations between the HbA1c and GA in pre-dialysis 
diabetic CKD patients compared with diabetic controls. There were positive and 
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significant correlations between the HbA1c and GA in controls and CKD patients, 
respectively. Furthermore, significant differences in the slopes of regression line 
among controls (slope = 3.52) and CKD patients (slopes in CKD stage 2, 3a, 3b 
and 4-5 = 4.00, 3.97, 4.22 and 4.14, respectively) was observed (p < 0.05, Figure 
1). This is demonstrated by increased steepness in slope of regression line between 
HbA1c and GA with decline in renal function.  
 
 
 
Moreover, as shown in Figure 2, a positive and significant correlation was 
observed between the HbA1c and eGFR [p < 0.05, Figure 2(A)], and a positive 
and significant correlation was observed between the GA/HbA1c ratio and eGFR 
[p < 0.05, Figure 2(C)]. In contrast, the GA showed no significant correlation with 
eGFR [p = 0.13, Figure 2(B)]. 
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Multivariate analysis was performed to evaluate which factors independently 
associated with the HbA1c or GA in CKD stage 3a, 3b and 4-5 (Table 3). In a 
reduced best-fit model where age, gender, BMI, serum glucose, hemoglobin, total 
protein, albumin, urine protein (excepted for nephrotic range proteinuria) and EPO 
dose were included, the HbA1c was significantly associated with BMI (p < 0.001), 
serum glucose (p < 0.001) and EPO (p = 0.02). And the GA was significantly 
associated with age (p = 0.03) and serum glucose (p < 0.001). 
 
 
 
Figure 3 shows a relationship between the HbA1c or GA level and weekly EPO 
dose after adjustment for covariates including age, gender, BMI, serum glucose, 
hemoglobin, total protein, albumin and urine protein. There was a significant and 
negative correlation between the HbA1c and weekly EPO dose [p = 0.02, Figure 
3(A)]. The GA, however, did not significantly correlate with EPO dose [p = 0.75, 
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Figure 3(B)]. 
 
 
 
We evaluated the weekly EPO dose altered the HbA1c level in CKD stage 3a, 3b 
and 4-5 (Figure 4). ROC analysis comparing the HbA1c level in control patients 
not received the EPO therapy with 32 patients who received EPO supplementation 
showed an AUC of 0.91 (95% CI 0.78 – 1.00, p < 0.001, Figure 4), and a cut-off 
value of weekly EPO dose was 6000 U/week and sensitivity and specificity of this 
value was 89% and 83%, respectively. 
 
IV. DISCUSSION 
In our study, the GA was shown to provide a more accurate marker to assess 
glycemic control even in pre-dialysis diabetic CKD patients, however, the HbA1c 
falsely underestimated the glycemic state. The HbA1c is currently the most widely 
used glycemic control marker, and the diabetic CKD patients were recommended 
the hemoglobin A1c (HbA1c) level of 7.0 % to prevent or delay progression of the 
microvascular complications4. In previous reports, the HbA1c assay has serious 
limitations with falsely underestimating glycemic state in ESRD patients on 
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hemodialysis.9, 18 However it was unclear whether the limitations of HbA1c 
extended to pre-dialysis diabetic CKD patients. Although the GA which not 
influenced by diseases of shortened RBC life span, and use of iron supplements 
and EPO therapy provides a reliable marker of glycemic control than the HbA1c 
in ESRD patients, there are not many studies on GA also provides a more 
appropriate assay to assess glycemic control in pre-dialysis diabetic CKD 
patients.12, 13 Our results provide a supportive evidence of relationships between 
the HbA1c or GA and serum glucose concentration at different CKD stages in 
pre-dialysis diabetic CKD patients and demonstrate that the HbA1c also 
underestimates significantly glycemic status in pre-dialysis diabetic CKD patients, 
especially CKD stage 4-5, whereas the GA was shown to correlate closely with the 
mean serum glucose concentration. 
The HbA1c primarily reflects mean serum glucose levels over time and does not 
reflect glycemic excursions. On the other hand, the GA correlates with maximum 
blood glucose levels in diabetic patients and reflects glycemic excursions as well 
as mean serum glucose.19 Recent the usefulness of the GA/HbA1c ratio (corrected 
for HbA1c) was shown to reflect the blood glucose variability and glycemic 
excursions within diabetic treatment. In addition, the GA/HbA1 is consistently 
increased in ESRD patients, further confirming the notion that HbA1c 
underestimates and inaccurately reflects long-term glycemia in this population. 
Therefore many clinical trials have compared the GA/HbA1c ratio between 
diabetic patients without nephropathy and ESRD patients on hemodialysis to find 
which glycemic control marker is more appropriate to reflect glycemic control.10, 17, 
20  We also assessed the GA/HbA1c ratio in pre-dialysis diabetic CKD patients. 
Freedman et al.20 reported that the GA/HbA1c ratio in diabetic patients without 
nephropathy was 2.22, and the results in ESRD patients on hemodialysis were 
2.93 which were significantly higher than controls (p < 0.05). Our data was 
reported the GA/HbA1c ratio was 2.5 ± 0.4 in diabetic patients without 
nephropathy, and the results in patients with CKD stage 3b and stage 4-5 were 2.7 
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± 0.6 and 3.0 ± 0.6, respectively which were significantly higher than in the 
controls (p < 0.05). In addition, the glucose/HbA1c ratio between patients in the 
controls and CKD stage 4-5 differed significantly, however the glucose/GA ratio 
was constant among groups. These results indicate that the HbA1c has a severe 
limitation with underestimation of glycemic control and the GA is to be a better 
indicator of glycemic control in pre-dialysis diabetic CKD patients, especially 
CKD stage 4-5. We also identified the reduction of HbA1c in advanced CKD 
stages by increased steepness in slope of regression line between the HbA1c and 
GA with decline in renal function (Figure 1). 
The HbA1c values are influenced by several factors that alter the survival of red 
blood cells.21 Many studies reported that several features including use of iron, 
EPO treatment,9, 18 uremia and blood transfusions8 in ESRD patients on 
hemodialysis contribute to reduction of 20-50% of normal RBC life-span, and the 
subsequent increased rate of hemoglobin turnover leads to decreased exposure 
time to ambient glucose that in turn lowers the extent of non-enzymatic binding of 
glucose to hemoglobin.22 In addition, the glycated rate of just-produced young 
erythrocyte is reported to be lower than that of old cells.23 As a result, the 
shortened RBC survival in ESRD patients lowers the HbA1c level, potentially 
making it unreliable in assessing glycemic control10. However the GA is not 
affected by RBC survival, iron supplement or EPO therapy commonly used in 
ESRD patients. Also, the GA was not associated with serum albumin 
concentration since the GA value is determined as ratio of GA concentration to 
total serum albumin.24 Consistent with previous study,10, 20 we also performed the 
multivariate analysis to investigate factors that influence on HbA1c and GA. The 
HbA1c was independently associated with serum glucose, weekly dose of EPO 
and BMI (Table 3), and the HbA1c level was shown to be significantly lower with 
increasing of EPO, while the GA was not associated with EPO (Figure 3). In 
addition, the GA was significantly associated with serum glucose and age (Table 
3). Kaysen et al.25 resulted the influence of proteinuria on serum albumin in 
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patients with nephrotic syndrome that albumin synthesis and fractional catabolic 
rate of albumin is increased, resulting in rapid albumin turnover and decreased GA 
values. Okada et al.26 also reported that nephrotic-range proteinuria (urine protein 
≥ 3.5 g/day) decreases the GA values independent of the glycemic state, however, 
non-nephrotic range proteinuria (urine protein ≤ 3.5 g/day) has no significant 
influence on the GA values in diabetic CKD patients. In our study, almost patients 
except for 15 people has urine protein ≤ 3.5 g/day, and we also demonstrated the 
result that GA was not affected by non-nephrotic range proteinuria. Furthermore 
some clinical trials reported that BMI negatively influenced GA levels in diabetic 
patients since the turnover of serum albumin may be increased in obese subjects, 
which sets serum GA at lower levels relative to plasma glucose concentrations.27, 
28 However, we failed to find a correlation between GA levels and BMI in our 
study. 
Additionally, we evaluated the weekly EPO dose altered the HbA1c level in 32 
patients who received EPO therapy. The cut-off value for weekly EPO dose was 
6000 U/week, and sensitivity and specificity of this value were 89% and 83%, 
respectively. Use of EPO in CKD patients under the health insurance system in 
Korea is allowed upto hemoglobin level of less than 11.0 mg/dL and considered 
mainly so that the hemoglobin level is maintained between 10 - 11 mg/dL. For this 
reason, patients who received EPO therapy in this study were just 32 people and 3 
months mean hemoglobin variation (delta Hb) in these patients was -0.01 mg/dL. 
Although the cut-off value for weekly EPO dose in this study was 6000 U/week 
and was relatively low level, it is very meaningful to measure the EPO dose 
altered the HbA1c level. Therefore, additional studies including more patients 
using EPO therapy and larger dose of EPO are needed to obtain the reliable cut-off 
value. 
In conclusion, our findings are interpreted that the GA rather than HbA1c is a 
better indicator of glycemic control even in pre-dialysis diabetic CKD patients, 
especially using weekly EPO dose more than 6000 U/week.  
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There are some limitations in this study. The mean serum glucose concentration 
was calculated by the mean values of the 3 monthly measurements of fasting 
serum glucose. Previous studies reported that fasting hyperglycemia is the 
predominant factor contributing to the overall diurnal hyperglycemia status in 
poorly controlled diabetic patients, whereas postprandial glucose elevations play 
the greater role in subjects with better glycemic control.29, 30 These discrepancy 
between fasting serum glucose and postprandial serum glucose is a weakness of 
this study. 
 
V. CONCLUSION 
In conclusion, our results indicate that the HbA1c underestimates the glycemic 
control state even in pre-dialysis diabetic CKD patients, especially those who are 
on EPO treatment and the GA might be an useful indicator of glycemic control in 
pre-dialysis diabetic CKD patients. 
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투석 전 단계의 당뇨병성 만성 신부전 환자에서 
혈당 조절의 지표로서 당화 알부민 
 
<지도교수 박 형 천> 
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배 성 창 
 
ABSTRACT 
 
 
배경 당뇨환자에서 적절한 혈당 조절은 신질환의 진행을 늦추고 심
혈관계 합병증을 줄여준다. 최근, 혈당 조절의 지표로서 일반적으로 
사용되고 있는 당화 혈색소가 혈액투석 치료를 받는 당뇨병성 말기 
신부전 환자에서 혈당을 정확히 측정하지 못한다는 여러 연구들이 있
었다. 반면, 당화 알부민은 말기 신부전 환자에서 흔히 나타나는 적혈
구 수명의 단축, 철분제의 및 조혈제의 사용 등에 의해 영향을 받지 
않기 때문에 말기 신부전 환자에서 혈당을 보다 정확히 측정한다는 
많은 보고들이 있었다. 본 연구에서는 투석 전 단계의 당뇨병성 만성 
신부전 환자에서 혈당 조절의 지표로서 당화알부민의 유용성을 연구
하고자 하였다. 
 
방법 2009년 3월부터 2012년 8월까지 본원 신장내과와 내분비내
과에서 3개월 이상 안정적으로 치료를 받고 있는 투석 전 단계의 제 
2형 당뇨 환자 497명이 연구에 참여되었다. 연구에 참여된 모든 환자
는 2012 KDIGO 에서 제시하는 만성 신부전 분류에 따라 5 그룹으로 
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나뉘어졌고, 나이, 성별, 체질량 지수, 혈액 검사, 소변 검사 및 약제 
복용력 등의 임상 정보와 함께 공복 혈당, 당화 혈색소, 당화 알부민 
등의 혈당 지표를 측정 하였다. 
 
결과 각 그룹별로 환자의 수는 1단계 (대조군)부터 4-5단계까지 각
각 168, 151, 76, 47, 55 명이었다. 모든 그룹에서 당화 혈색소와 당화 
알부민은 유의한 양의 상관 상관관계를 보였지만 당화 혈색소와 당화 
알부민 사이의 회귀 곡선의 기울기는 신부전이 진행함에 따라 통계적
으로 유의하게 커지는 양상을 보였다. (대조군 vs. 그 외 만성 신부전 
그룹: p < 0.05). 당화알부민/당화혈색소의 비와 평균 공복 혈당/당화
혈색소의 비는 3b단계와 4-5단계에서 대조군에 비해 유의하게 높았
고 당화알부민/당화혈색소의 비는 신부전이 진행함에 따라 증가하는 
경향을 보였다 (r = 0.22, p < 0.001). 하지만 평균 공복 혈당/당화알부
민의 비는 모든 그룹에서 일정하였다 (r = 0.07, p = 0.06). 몇 가지 인
자들을 보정한 후에 시행한 다변량 분석에서는 조혈제가 당화혈색소
와 통계적으로 유의하게 관련이 있었고 (p = 0.02), 이 때 당화혈색소 
값을 변화시키는 조혈제 용량을 ROC curve 를 통해 구한 결과 cut 
off 값은 주당 6000 단위로 나타났다 (AUC = 0.91, 95% CI 0.78 - 
1.00). 
 
결론 투석 전 단계의 당뇨병성 만성 신부전 환자에서 특히 조혈제
를 사용하는 경우, 당화 혈색소는 혈당을 적절히 반영하지 못하며, 당
화 알부민이 당화 혈색소보다 유용한 혈당 조절의 지표일 수 있다. 
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